Navigation Links
Bionovo Receives Positive Guidance from FDA on Menerba®
Date:8/30/2010

es, prior to clinical dosing, Bionovo will complete a 28 day bioequivalence study in rats. The agency also requested that Bionovo provide selected batch records for review. It is important to remember that Menerba was effective in Phase 2 and showed no signs of safety concerns in human or animal studies to date."

"With the CMC preparations complete, we can now turn our attention to finalizing the communication on the clinical trial design with the FDA in the coming weeks," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer. "We expect to be able to initiate pivotal trials by year end."

Previously, the Company received final guidance from the European Medicines Agency (EMA) in order to advance Menerba to Phase 3 clinical trials in Europe. The EMA guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba. With this EMA guidance, and the FDA guidance, the Company is now preparing for pivotal clinical trials in the U.S. and Europe.

About Menerba

Menerba is an oral, botanical-derived drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market, which have been shown to increase the risk for breast and uterine cancers. Clinical tests conducted thus far, following the specific guidance of the FDA, have indicated that Menerba is effective and safe.

About Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces Reverse Stock Split
2. Bionovo Announces Publication Describing Menerbas Effect on Neural Pathways Related to Temperature Regulation
3. Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe
4. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2010 Financial Results on Wednesday, August 4, 2010
5. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Bionovo, Inc. to Announce Fourth Quarter and Fiscal Year 2009 Financial Results on Monday, March 15, 2010
8. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
9. Bionovo Announces Third Quarter 2009 Highlights and Financial Results
10. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
11. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015  Seeger Weiss LLP is reporting that ... a warning letter to C.R. Bard, the manufacturer of ... strides to correct violations the agency found at two of ... after the FDA cited them during Inspectional Observations that occurred ... Tempe, AZ , location and on October ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
(Date:7/31/2015)... According to a new market research report " Sterilization ... Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables (Indicators, Detergents, ... 2020", published by MarketsandMarkets, The Sterilization Equipment Market is expected ... CAGR of 7.6%.from 2015 to 2020. Browse ... and 37 F igures spread ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4
... , STAMFORD, Conn. , Jan. 27 ... and Drug Administration (FDA) 510(k) approval has been received for the ... in the U.S.  A fully automated digital table and upright ... comparison to other general radiographic systems*.  It also includes special design ...
... , LAS VEGAS , ... of research and an extensive open-label weight loss study, ... Livea® , a doctor-developed, non-prescription, patent-pending appetite-control supplement that is ... (Photo: http://www.newscom.com/cgi-bin/prnh/20100127/NY44298 ) , New research in neuropeptides ...
Cached Medicine Technology:Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 2Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 3Now Approved: Fujifilm's FDR AcSelerate Direct Digital DR System 4WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement 2WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement 3WellWorld Science(R) Announces U.S. Launch of Livea(R),a Safe and Natural Appetite Control Supplement 4
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... at its new True North Conference Center. The medical community, social workers, law ... community may be more aligned in the effort to better understand and combat ...
(Date:7/31/2015)... ... 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc Board Exam ... , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an already robust ... the exam easy and painless. MDLinx offers thousands of board-exam style questions and ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has ... alike on various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, ... procedures like Botox and fillers. , Staying up to date with the ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2
... reduce risk of genetic condition that can lead to ... A simple blood test early in life could identify ... high cholesterol levels and greatly increases the risk of ... , Drug treatment could eventually be started to reduce ...
... Sept. 13 Arrow International,Inc. (Nasdaq: ARRO ) ... today on the WHITE proxy card for its planned ... to re-elect the Arrow Board of,Directors, who are committed ... of Arrow common stock to shareholders once the,merger is ...
... value of Basic and Standard,Options, WASHINGTON, Sept. ... reliability and value from the Blue Cross,and Blue ... Program or FEP(R)) in 2008., FEP health ... for,FEP BlueVisionSM will stay essentially unchanged from last ...
... Services:, WHO: Kenneth Moritsugu, M.D. M.P.H., Acting U.S Surgeon ... M.D., F.A.A.P., President, American ... Schneider, J.D., Acting Assistant Secretary, HHS ... Elizabeth Cotsworth, Director, Office of Radiation and Indoor ...
... shows , , THURSDAY, Sept. 13 (HealthDay News) -- The HIV ... of sexual partners, U.S. researchers report. , More than half ... 2005 were among gay men, a team at the University ... in five gay men living in cities may be HIV-positive. ...
... CHAPEL HILL, N.C., Sept. 13 Building and ... in organizational success. It begins,with setting up a ... people, properly communicating goals and maintaining frequent,contact with ... that meets both,organizational and personal goals. The Best ...
Cached Medicine News:Health News:Screening Proposed for Childhood Cholesterol Levels 2Health News:Screening Proposed for Childhood Cholesterol Levels 3Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 2Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 3Health News:Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors 4Health News:Federal Employee Program Maintains Low Health Premiums In 2008 2Health News:Federal Employee Program Maintains Low Health Premiums In 2008 3Health News:Acting Surgeon General Announces National Initiatives to Protect Children by Reducing Exposure to Secondhand Smoke 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2
... The proper gel is ... electrode when working with pH ... The specific chloride ion concentration ... is required for proper function ...
The IgA in vitro diagnostic enzyme immunoassay is intended for the qualitative detection of anti-human tTG IgA antibodies in human serum as an aid in the diagnosis of CD....
...
... The FIDIS system and its ... simultaneously and on the same sample, ... dedicated to all types of laboratories ... than today their daily routine, as ...
Medicine Products: